Abiopharma

MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum

New Form SCHEDULE 13G/A - Apyx Medical Corp Filed: 2026-01-20 AccNo: 0000906304-26-000004 Size: 10 KB

Valneva SE ADR (VALN) Files Form 6-K

PainReform Ltd. (PRFX) Files Form 6-K

Akanda Corp (AKAN) Files Form 6-K

(85% Positive) Phio Pharmaceuticals Corp. (PHIO) Announces Clinical Development Update

(10% Negative) Lipocine Inc. (LPCN) Announces Delay in early Development Timeline Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial

Aurora Secures EU Community Plant Variety Rights for Two Proprietary Cannabis Varieties

Hurlburt Elizabeth 🔴 sold 5.8K shares of CorMedix Inc. (CRMD) at $7.15 Transaction Date: Jan 12, 2026 | Filing ID: 005426

Director Todisco Joseph 🟡 adjusted position in 40.1K shares (1 derivative) of CorMedix Inc. (CRMD) at $7.15 Transaction Date: Jan 12, 2026 | Filing ID: 005425

FMR LLC 🔴 sold 4.6M shares (9 derivative) of Structure Therapeutics Inc. (GPCR) Transaction Date: Jan 15, 2026 | Filing ID: 016062

Director Schall Thomas J. 🟢 acquired 21.6K shares of Immuneering Corp (IMRX) at $4.67 Transaction Date: Jan 15, 2026 | Filing ID: 000014

Illumina, Inc. - Illumina secures CMS reimbursement forTruSight™ Oncology Comprehensive, expanding access to precision oncology

New Form 424B5 - Tharimmune, Inc. Filed: 2026-01-20 AccNo: 0001493152-26-002773 Size: 578 KB